Malignant Mesothelioma Asbestos
existing asbestos
months
EU actions
low quantities of asbestos fibres
asbestos related occupational health threats
treatment of malignant mesothelioma
EMA
consumers
therapy-resistant disease
curative therapy
FDA
poor median survival time
prolonged average survival
limited adverse events
therapy Orphan Designation
limited adverse effects
fatal disease
clinical results
Millions of workers
clinical trial
promising personalised immunotherapy
DC-based immunotherapy
major occupational carcinogens
autologous dendritic cells
allogeneic tumour cell lysate
prospects
Netherlands
Erasmus MC
market approval
signs of illness
Rotterdam
extensive history
international partners
registration package
standard of care
novel immuno therapeutic approach
cisplatin
department of pulmonary diseases
collaboration
risk
combination of pemetrexed
European Union
phase
aggressive treatments
built environment
project
Chemotherapy
Inhalation
date
deaths
incidence
resolution
years
measures
objective
IARC
execution